BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

March 11, 2013 7:00 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) gained $3.68 to $172.38 after it and partner Swedish Orphan Biovitrum AB (SSE:SOBI) announced FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA date in 4Q13, a specific date is not disclosed.

Swedish Orphan was off SEK1.30 to SEK37.90 last week...